According to a new report by Polaris Market Research, the global artificial intelligence in cancer diagnostics market was valued at USD 272.75 million in 2025 and is projected to reach USD 2,165.56 million by 2034, expanding at a CAGR of 25.9% over the forecast period. Growth is underpinned by the rising global incidence of cancer, growing demand for precision medicine, and accelerating advancements in machine learning and deep learning algorithms across key end-use industries.

What Is Driving Artificial Intelligence in Cancer Diagnostics Market Growth?

Demand is climbing as the rising global cancer burden converges with growing adoption of AI-powered imaging and pathology tools. Manufacturers and healthcare providers are prioritizing early cancer detection, pushing AI diagnostics adoption across hospitals, diagnostic centers, and research institutes worldwide. Polaris analysts note that the World Health Organization's estimate of roughly 20 million new cancer cases in 2022 positions the segment for sustained double-digit growth through 2034, with screening & diagnosis emerging as the largest revenue contributor and tumor identification posting the fastest incremental gains.

Key Trends Shaping the Artificial Intelligence in Cancer Diagnostics Industry

AI-Powered Imaging and Pathology Innovation

Vendors are integrating AI with advanced imaging technologies such as MRI and CT scans to assist radiologists and pathologists, reflecting a broader wave of product innovation and technology advancement across precision oncology.

Government Funding and Regulatory Support

Public initiatives such as the U.S. Cancer Moonshot program and European Investment Bank-backed diagnostics funding are shaping the regulatory landscape and accelerating the deployment of AI-driven diagnostic tools.

Consolidation Through Strategic Acquisitions

Major healthcare and technology players are acquiring specialized AI diagnostics firms to deepen their digital pathology capabilities, a shift reflected in the market's competitive landscape and near-term investment outlook.

Market Segmentation: Breaking Down the Artificial Intelligence in Cancer Diagnostics Market

Polaris segments the artificial intelligence in cancer diagnostics market by application, cancer type, end use, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Application

The Screening & Diagnosis segment led the market in 2025, accounting for 37.0% of revenue, on the strength of AI's integration with medical imaging and pathology for early cancer detection. The Tumor Identification segment is projected to expand at the fastest CAGR of 26.6% through 2034 as improvements in tumor detection and characterization techniques accelerate adoption.

By Cancer Type

The Breast Cancer segment remains the dominant cancer type, holding a 26.0% share in 2025 on the back of high global incidence and regular mammography screening programs. The Lung Cancer segment is gaining share, with the fastest projected CAGR of 26.4% through 2034, signaling where near-term demand — and search intent around "AI lung cancer detection" — is shifting.

By End Use

Among end-use categories, Hospitals captured the largest share of the market, driven by widespread integration of AI algorithms into clinical workflows to address the global shortage of healthcare professionals, while Diagnostic Centers and Medical Research Institutes are expected to post meaningful incremental growth as AI-powered screening expands beyond hospital settings.

Regional Outlook: Where Is Artificial Intelligence in Cancer Diagnostics Growing Fastest?

North America led the market in 2025 with a 39.0% share, supported by advanced healthcare infrastructure and significant investment in healthcare IT, while Asia Pacific is expected to post the fastest CAGR of 27.2% through 2034, driven by rising healthcare expenditure and improved cancer testing services. Within North America, the U.S. remains the largest single market; within Asia Pacific, China and Japan are the primary growth engines. Europe rounds out the top three, supported by institutional AI research collaborations and public funding for early cancer detection.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/artificial-intelligence-in-cancer-diagnostics-market 

Competitive Landscape: Leading Artificial Intelligence in Cancer Diagnostics Companies

Key players profiled in the report include Microsoft Corporation, IBM Corporation, Siemens Healthineers AG, GE Healthcare Technologies Inc., and Tempus Labs, Inc., who are focusing on partnerships, product launches, and acquisitions to strengthen market position across the Screening & Diagnosis and Breast Cancer segments outlined above. Recent moves include Roche's May 2026 agreement to acquire PathAI for up to USD 1.05 billion to strengthen its AI-driven cancer diagnostics portfolio, and Universal Diagnostics' January 2026 €30 million funding round from the Spanish government to advance its AI-powered liquid biopsy platform, both aimed at deepening share in North America and Europe.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the AI cancer diagnostics market forecast, this report benchmarks market share, segment-level pricing, and forecast data — by application, cancer type, end use, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking digital pathology as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Gabapentin Market

Hard Coating Market

Kimchi Market

Pad-mounted Switchgear Market

Hard Coating Market

Solar Panels Market

Functional Endoscopic Sinus Surgery Market

Rising Cases of Cardiovascular Diseases across the Globe to Fuel Need for Neuralgia Treatment

Riflescope & Red dot sight market